spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  OSI Pharmaceuticals 

 HSMN NewsFeed - 9 Sep 2022
Nouscom Strengthens Leadership Team with the Appointments of Sven Gogov, MD, as Chief Medical Officer and Maria Arce-Tomas, PhD, as VP, Head of Regulatory Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Dec 2020
HiberCell Bolsters Leadership Team with Appointment of Joseph Talamo as Chief Financial Officer and Promotion of Ari Nowacek, M.D., Ph.D., to Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Apr 2020
FoRx Therapeutics AG Raises EUR 10 Million Seed Round and Becomes First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 10 Sep 2019
ORIC Pharmaceuticals Appoints Dominic Piscitelli as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 May 2018
Aptinyx Promotes David Houck to Chief Development Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 21 Mar 2018
TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 10 Jul 2017
Gamida Cell Inc. Names Ronit Simantov, M.D. as Chief Medical Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 13 Mar 2017
Lycera Announces the Appointment of Pablo J. Cagnoni, M.D., to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Dec 2016
Mission Therapeutics Appoints Colin Goddard as Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Mar 2016
Accera Appoints Ernest Wong, Ph.D., as Head of Corporate Development
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 1 Apr 2015
Iroko Pharmaceuticals Appoints New Member to Company’s Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Nov 2014
Agilis Biotherapeutics Names Former Shire Executive Dr. Gregory Robinson as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 May 2014
Ventrus Biosciences to Merge With Assembly Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 3 Mar 2014
Genentech Provides Update on Phase III Study of Onartuzumab in People with Specific Type of Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Jan 2014
Champions Oncology Names Angela Davies, M.D., Chief Medical Officer
Biopharmaceuticals Personalized Medicine Personnel
 HSMN NewsFeed - 29 May 2013
Ophthotech Raises $175 Million to Finance the Pivotal Phase 3 Program for Fovista(TM) Anti-PDGF Combination Therapy in Wet AMD
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 15 Feb 2013
Onyx Pharmaceuticals Appoints Dr. Pablo Cagnoni as Executive Vice President, Global Research & Development and Technical Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Jan 2013
Bionor Pharma Appoints Anker Lundemose as President and Chief Executive Officer
Biopharmaceuticals HIV/AIDS Personnel
 HSMN NewsFeed - 23 Jul 2012
Addition of Tarceva(R) (erlotinib) to Nexavar(R) (sorafenib) did not Provide Additional Benefit to Patients with Unresectable Liver Cancer Versus Nexavar alone in Phase 3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Jul 2012
Coferon, Inc. Announces $12 Million Series B Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 25 Apr 2012
Threshold Pharmaceuticals Appoints Robert Simon as Senior Vice President of Regulatory Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Jul 2011
Nils Bergenhem, PhD - Newly Appointed President and Chief Scientific Officer of Egenix, Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jul 2011
Agennix Hires Christine Boisclair as Senior Vice President of Global Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jun 2011
Tarceva Nearly Doubled the Time People With a Genetically Distinct Type of Lung Cancer Lived Without Their Disease Getting Worse
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jan 2011
Optimer Pharmaceuticals Announces Key Additions to Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Dec 2010
Human Genome Sciences Appoints Colin Goddard, Ph.D., to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Nov 2010
Infinity Augments Executive Leadership Team, Appointing New Chief Medical Officer and New Vice President, Product Development and Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Sep 2010
Mersana Therapeutics Appoints Nicholas Bacopoulos President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jun 2010
Astellas Completes Acquisition of OSI Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 8 Jun 2010
Astellas Announces Successful Completion of Tender Offer for Shares of OSI
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 May 2010
Epizyme Appoints Mikel Moyer, Ph.D., Vice President of Molecular Discovery
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 May 2010
VIVUS Appoints Michael Miller to Senior Vice President and Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Apr 2010
OSI Pharmaceuticals Announces That Tarceva(R) Received Approval in the European Union for Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Mar 2010
Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Directors
Biopharmaceuticals Mergers & Acquisitions Personnel
 HSMN NewsFeed - 19 Mar 2010
OSI Pharmaceuticals Announces That Tarceva(R) Received a Positive Opinion from Health Authorities in the European Union for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 2 Mar 2010
OSI Pharmaceuticals Board of Directors to Review Astellas' Unsolicited Tender Offer
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 2 Mar 2010
Astellas Pharma Inc. Commences Tender Offer to Acquire All Outstanding Shares of OSI Pharmaceuticals for $52 per Share in Cash
Biopharmaceuticals Mergers & Acquisitions Litigation
 HSMN NewsFeed - 1 Mar 2010
OSI Pharmaceuticals Confirms Receipt of Unsolicited Proposal From Astellas Pharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 1 Mar 2010
Astellas Pharma Inc. Offers to Acquire OSI Pharmaceuticals for $52.00 Per Share in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 15 Jan 2010
FDA Extends Review Period for Tarceva Application for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Nov 2009
NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Nov 2009
OSI Pharmaceuticals Announces Tarceva to Be Reviewed by the FDA's Oncologic Drugs Advisory Committee for Use as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Sep 2009
AVEO Pharmaceuticals Appoints William J. Slichenmyer, M.D., Sc.M., as Chief Medical Officer and Robert C. Young, M.D., to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Sep 2009
OSI Pharmaceuticals Initiates Phase III Registration-Oriented Study for OSI-906 in Adrenocortical Carcinoma and Phase I/II Study in Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Aug 2009
New Data from Phase III SATURN Study Showed Tarceva Extended Survival in Patients with Advanced Non-Small Cell Lung Cancer When Used Immediately after Initial Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jul 2009
New Data from Phase III SATURN Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Mar 2009
OSI Pharmaceuticals Files Patent Infringement Lawsuits Against Teva Pharmaceuticals USA and Mylan Pharmaceuticals
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 19 Mar 2009
OSI Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Tarceva as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Nov 2008
Tarceva(R) (erlotinib) Endorsed by the U.K.'s National Institute for Health and Clinical Excellence for Use in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Aug 2008
Lung Cancer Epidemic Looming in Asia?
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jul 2008
Xclair(R) Reported to Be Safe and Effective in Study Published in European Journal of Dermatology
Biopharmaceuticals Dermatology Oncology
 HSMN NewsFeed - 7 Mar 2008
Abbott to Collaborate With Genentech, Roche and OSI on Molecular Test for Lung Cancer Therapy Response
Diagnostics Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Dec 2007
OSI Pharmaceuticals Announces Launch Date of Tarceva(R) (erlotinib) in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Dec 2007
OncoVista Licenses Phase II Clinical-Stage Drug from OSI Pharmaceuticals
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 8 Nov 2007
Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Nov 2007
AVEO Pharmaceuticals Appoints David Johnston as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Oct 2007
Tarceva(R) (erlotinib) Earns Approval for Lung Cancer Patients in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Oct 2007
OSI Pharmaceuticals Provides Additional Information about US Sales of Tarceva
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Sep 2007
OSI Pharmaceuticals Announces Patent Term Extension for Tarceva(R) (erlotinib)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Sep 2007
OSI Pharmaceuticals Summarizes Data Presented on Tarceva(R) (erlotinib) at the 12th World Congress on Lung Cancer Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Sep 2007
Aradigm and CyDex Sign Development Collaboration Agreement
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 4 Sep 2007
Roche's Tarceva(R) Delivers Longer Life for Lung Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Aug 2007
Ophthotech Raises $36 Million; In-Licenses Two Compounds for Macular Degeneration
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 27 Jul 2007
OSI Pharmaceuticals Announces Agreement to Divest Anti-Platelet Derived Growth Factor (PDGF) Program
Biopharmaceuticals Ophthalmology Acquisitions
 HSMN NewsFeed - 12 Jul 2007
Mersana Therapeutics, Inc. Appoints Pharmaceutical Industry Veteran Nicholas G. Bacopoulos, Ph.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jun 2007
Plexxikon Expands Management Team and Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Jun 2007
OSI Pharmaceuticals Begins Clinical Development Program of OSI-906 in Patients with Advanced Solid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Jun 2007
Seattle Genetics Adds Industry Veterans John P. McLaughlin and Daniel G. Welch to its Board of Directors and Promotes Eric Dobmeier to Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Jun 2007
OSI Pharmaceuticals Announces the Election of Kenneth B. Lee, Jr. to Its Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jun 2007
Biodesix, Inc. Announces Breakthrough In Molecular Diagnostics For Lung Cancer
Diagnostics Oncology
 HSMN NewsFeed - 5 Jun 2007
OSI Pharmaceuticals Summarizes Data on Tarceva(R) (erlotinib) at the 2007 American Society of Clinical Oncology (ASCO) Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2007
Achillion Appoints OSI Executive Robert Van Nostrand to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Apr 2007
OSI Pharmaceuticals Announces Pivotal Phase III Tarceva(R) Study Published in the Journal of Clinical Oncology Showed Survival Improvement in Patients with Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Mar 2007
Dr. Robert Langer Named as Chairman of Boston Life Sciences, Inc. Newly Formed Science and Technology Committee of the Board of Directors
Devices Personnel
 HSMN NewsFeed - 20 Mar 2007
Allos Therapeutics Appoints Pablo J. Cagnoni, M.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Jan 2007
OSI Pharmaceuticals Announces European Regulatory Approval of Tarceva(R) for Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Jan 2007
OSI Pharmaceuticals Licenses Its Glucokinase Activator Program for the Treatment of Type 2 Diabetes to Eli Lilly and Company
Biopharmaceuticals Endocrinology Licensing
 HSMN NewsFeed - 5 Jan 2007
Lilly and OSI Pharmaceuticals Announce Licensing Agreement
Biopharmaceuticals Endocrinology Licensing
 HSMN NewsFeed - 18 Dec 2006
OSI Pharmaceuticals Announces Appointment of Pablo J. Cagnoni, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Dec 2006
OSI Pharmaceuticals Announces That Tarceva(R) Received Positive Opinion from Health Authorities in European Union for the Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Dec 2006
CyDex Announces Captisol Technology Used in Recently Launched Injection Formulation of Antipsychotic Medication ABILIFY(R) (aripiprazole)
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 14 Dec 2006
OSI Pharmaceuticals Grants License to Bristol-Myers Squibb under Dipeptidyl Peptidase IV (DPIV) Patent Portfolio for the Treatment of Type 2 Diabetes
Biopharmaceuticals Licensing
 HSMN NewsFeed - 12 Dec 2006
Interim Analysis of Phase III Trial Shows Avastin Plus Interferon Therapy Improved Progression-Free Survival in Patients With Previously Untreated Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Nov 2006
Adnexus Therapeutics Appoints Bruce A. Silver, MD, FACP as Medical Director
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Nov 2006
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Nov 2006
Introgen Obtains Exclusive License to Therapies Combining Epidermal Growth Factor Drugs and Tumor Suppressor Genes
Biopharmaceuticals Licensing Oncology
 HSMN NewsFeed - 2 Nov 2006
Enzon Pharmaceuticals Announces Second Investigational New Drug Application Approved for Novel rhMBL
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Oct 2006
Hana Biosciences Licenses Drug Candidate for the Prevention and Treatment of EGFR Inhibitor-Associated Skin Rash
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 11 Oct 2006
FDA Approves Avastin(R) in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Sep 2006
OSI Pharmaceuticals Launches Study of Tarceva(R) as Adjuvant Treatment for Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jul 2006
Amicus Therapeutics Adds Glenn P. Sblendorio to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jun 2006
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jun 2006
OSI Pharmaceuticals and Pfizer Announce Phase IV Macugen(R)(pegaptanib sodium injection) Maintenance Trial in Neovascular Age-Related Macular Degeneration (AMD)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 Jun 2006
Preliminary Topline Efficacy Results from Phase II Data Show Macugen(R) (pegaptanib sodium injection) Maintained or Improved Vision in over 90 Percent of Patients with Macular Edema Associated with Central Retinal Vein Occlusion (CRVO)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 25 May 2006
Genentech Submits Supplemental Biologics License Application for Avastin With Chemotherapy in First-Line Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 May 2006
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 May 2006
OSI Pharmaceuticals Summarizes Macugen(R) (pegaptanib sodium injection) Data Presented at Association for Research in Vision and Ophthalmology (ARVO) Meeting
Biopharmaceuticals Ophthalmology
Return to NewsFeed  

 Additional items found! 115

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 115 additional stories matching:
OSI Pharmaceuticals
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.